|
|
Studies
Over 2,000 clinical studies
worldwide have proven the success of therapeutic lasers in the healing of
neural muscular-skeletal conditions. Theralase® has performed a blinded
randomized control study on chronic knee pain proving the clinical
efficacy and safety of Theralase® therapeutic laser technology and
achieving FDA 510(k) approval.
Efficacy of
904 nm Gallium Arsenide Low Level Laser Therapy in the Management of
Chronic Myofascial Pain in the Neck: A Double‐Blind and Randomized
Controlled Trial
Background and Objectives: A prospective, double blind, randomized, and
controlled trial was conducted in patients
with chronic myofascial pain syndrome (MPS) in the neck to evaluate the
effects of infrared low level 904 nm Gallium‐
Arsenide (Ga‐As) laser therapy (LLLT) on clinical and quality of life
(QoL).
Study Design/Patients and Methods: The study group consisted of 60 MPS
patients. Patients were randomly assigned to
two treatment groups: Group I (actual laser; 30 patients) and Group II
(placebo laser; 30 patients). LLLT continued daily
for 2 weeks except weekends. Follow‐up measures were evaluated at
baseline, 2, 3, and 12 weeks. All patients were
evaluated with respect to pain at rest, pain at movement, number of
trigger points (TP), the Neck Pain and Disability
Visual Analog Scale (NPAD), Beck depression Inventory (BDI), and the
Nottingham Health Profile (NHP).
Results: In active laser group, statistically significant improvements
were detected in all outcome measures compared
with baseline (P < 0.01) while in the placebo laser group, significant
improvements were detected in only pain score at rest at the 1
week later of the end of treatment. The score for self‐assessed
improvement of pain was significantly different between
the active and placebo laser groups (63 vs. 19%) (p < 0.01).
Conclusion: This study revealed that short‐period application of LLLT is
effective in pain relief and in the improvement of
functional ability and QoL in patients with MPS.
Action of 904 Nm Diode Laser In Orthopaedics and Traumatology
Objective: The semiconductor or laser diode (GaAs, 904 nm) is the most
appropriate choice in pain reduction therapy.
Summary Background Data: Low power density laser acts on the
Prostaglandins synthesis, increasing the change of
PGG2 and PGH2 Periossidos into PGI2 (also called Prostaciclyn or
Endoprostol). The last one is the main product of the
Arachidonic acid into the endothelial cells and into the smooth muscular
cells of the vessel walls having a vasodilating
and anti‐inflammatory action.
Methods: Treatment was carried out on 447 cases and 435 patients (250
women and 185 men) in the period between
20.05.1987 and 31.12.1999. The patients, whose age ranged from 25 to 70,
with a mean age of 45 years, were suffering
from rheumatic, degenerative and traumatic pathologies as well as
cutaneous ulcers. The majority of the patients had
been seen by orthopaedists and rheumatologists and had undergone x‐ray
examination. All patients had received drugbased
treatment and/or physiotherapy, with poor results. Two thirds were
experiencing acute symptomatic pain, while
the others presented a chronic pathology with recurrent crises. We used a
pulsed diode laser, GaAs 904 nm wavelength.
Frequency of treatment: 1 application per day for 5 consecutive days,
followed by a 2‐day interval. In the evaluation of
the results the following parameters have been considered: disappearance
of spontaneous and induced pain, anatomic
and functional evaluation of the joints, muscular growth, verbal rating
scales, hand dinamometer, patient's pain diary.
Results: Very good results were achieved especially with cases of
symptomatic osteoarthritis of the cervical vertebrae,
with sport‐related injuries, with epicondylitis, and with cutaneous
ulcers; also, last but not of least importance, with
cases of osteoarthritis of the coxa.
Conclusions: Treatment with 904 nm diode laser has substantially reduced
the symptoms as well as improved the quality
of life of the patient, thus postponing the need for surgery.
Effects of 904‐Nm Low‐Level Laser Therapy in the Management of Lateral
Epicondylitis: A Randomized Controlled Trial.
Objective: The aim of this study was to evaluate the effectiveness of
904‐nm low‐level laser therapy (LLLT) in the
management of lateral epicondylitis.
Background Data: Lateral epicondylitis is characterized by pain and
tenderness over the lateral elbow, which may also
result in reduction in grip strength and impairment in physical function.
LLLT has been shown effective in its therapeutic
effects in tissue healing and pain control.
Methods: Thirty‐nine patients with lateral epicondylitis were randomly
assigned to receive either active laser with an
energy dose of 0.275 J per tender point (laser group) or sham irradiation
(placebo group) for a total of nine sessions. The
outcome measures were mechanical pain threshold, maximum grip strength,
level of pain at maximum grip strength as
measured by the Visual Analogue Scale (VAS) and the subjective rating of
physical function with Disabilities of the Arm,
Shoulder and Hand (DASH) questionnaire.
Results: Significantly greater improvements were shown in all outcome
measures with the laser group than with the
placebo group (p < 0.0125), except in the two subsections of DASH.
Conclusion: This study revealed that LLLT in addition to exercise is
effective in relieving pain, and in improving the grip
strength and subjective rating of physical function of patients with
lateral epicondylitis.
Acute
Cervical Pain is Relieved with Gallium Arsenide (GaAs) Laser radiation: A
Double Blind Preliminary Study
Study Design/Patients and Methods: Seventy‐one patients with acute
cervical pain were randomized in two groups.
Group A, 37 patients were irradiated with a pulsed GaAs diode laser, 904
nm, pulse width 200 nsec, pulse frequency
10,000 Hz, peak power of 20 W, average power 40 mW, spot size 150 um2 in
area (incident power density of
approximately 26 W/cm2) and an angle of divergence of 6o. The laser was
applied in the point technique with a dose of 4
J/cm2 per point in the area of pain. Group B, 34 patients, was treated
with sham irradiation with a deactivated laser
system. Neither the patients nor the operator knew which group each
patient was randomly assigned to. The use of
analgesic drugs and physical therapy was excluded in both groups. Pain was
evaluated through a linear colour scale.
Laser treatment was considered effective when pain relief was more than
60%.
Results: The treatment was effective in 94.59% of patients in group A and
38.24% of group B (p < 0.0019). The pain was
relieved completely in 67.56% of patients in group A and in 17.65% in
group B. In patients in whom the response to the
treatment was effective, the pain returned in the six months following
treatment in 14.28% of Group A, but in 58.33% of
group B (p < 0.005). No side effects were observed.
Conclusion: These results suggest that GaAs laser radiation is an
efficient and safe treatment for patients with acute
cervical pain. Six years have passed since we incorporated the GaAs laser
into our therapeutic arsenal and up to date we
have irradiated more than two thousand patients with different kinds of
pain and pain sites. The aim of this work is to
evaluate the real therapeutic effect versus the placebo effect of laser
therapy in patients with acute cervical pain in both
the immediate effect and the possible latency of the pain relief with
LLLT.
Efficacy of Low Power Laser Therapy in Fibromyalgia: A Single‐Blind,
Placebo‐Controlled Trial
Objective: The aim of this study was to evaluate the effectiveness of
904‐nm low‐level laser therapy (LLLT) in the
management of fibromyalgia.
Background: Low energy lasers are widely used to treat a variety of
musculoskeletal conditions including fibromyalgia,
despite the lack of scientific evidence to support its efficacy.
Methods: A randomised, single‐blind, placebo‐controlled study was
conducted to evaluate the efficacy of low‐energy
laser therapy in 40 female patients with fibromyalgia. Patients with
fibromyalgia were randomly allocated to active (Ga‐
As) laser or placebo laser treatment daily for two weeks except weekends.
Both laser and placebo laser groups were
evaluated for the improvement in pain, number of tender points, skinfold
tenderness, stiffness, sleep disturbance,
fatigue, and muscular spasm.
Results: In both groups, significant improvements were achieved in all
parameters (p<0.05) except sleep disturbance,
fatigue and skinfold tenderness in the placebo laser group (p>0.05). It
was found that there was no significant difference
between the two groups with respect to all parameters before therapy
whereas a significant difference was observed in
parameters as pain, muscle spasm, morning stiffness and tender point
numbers in favour of laser group after therapy
(p<0.05). None of the participants reported any side effects.
Conclusion: Our study suggests that laser therapy is effective on pain,
muscle spasm, morning stiffness, and total tender
point number in fibromyalgia and suggests that this therapy method is a
safe and effective way of treatment in the cases
with fibromyalgia.
|
